Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
KI-Analyse von METACRINE INC
Wähle eine Analyse aus und der finAgent liefert dir tiefgehende Einblicke dazu!
Neuste KI Analysen zu METACRINE INC
Für dieses Unternehmen sind noch keine KI-Threads verfügbar.